Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension by Richard Channick, MD, Sarah Medrek, MD, Marion Delcroix, MD, Sean Gaine, MD, Pavel Jansa, MD, PhD, Irene Lang, MD, Vallerie McLaughlin, MD, Sanjay Mehta, MD, Tomas Pulido, MD, Bhagavatula Sastry, MD, Rogerio Souza, MD, PhD, Adam Torbicki, MD, Carol Zhao, MS, Paul Strachan, MD, Peter Agron, PhD, Joseph Yen, PhD, Olivier Sitbon, MD, PhD

Subjects: Get full text

Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies by Kelly M. Chin, Richard Channick, Nick H. Kim, Rose Ong, Stefano Turricchia, Nicolas Martin, Lada Mitchell, Vallerie V. McLaughlin

Subjects: Get full text

SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation by Robert P. Frantz, Shashank S. Desai, Gregory Ewald, Veronica Franco, Antoine Hage, Evelyn M. Horn, Shane J. LaRue, Michael A. Mathier, Stacy Mandras, Myung H. Park, Ashwin K. Ravichandran, Joel D. Schilling, I‐wen Wang, Ronald Zolty, Gabriela Gomez Rendon, Mark A. Rocco, Mona Selej, Carol Zhao, J. Eduardo Rame

Subjects: Get full text

Development and validation of an LC-MS/MS method for the simultaneous estimation of tadalafil and macitentan in rat plasma: Greenness assessment and design of experiment approach by Sravanthi Gandu, Kumaraswamy Gandla, Lalitha Repudi

Subjects: Get full text

Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-bli... by Mandana Kashaki, Arash Mohazzab, Mohammad Radgoudarzi, Arash Bordbar, Sama Dabbagh

Subjects: Get full text